Compare BCRX & TRIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCRX | TRIN |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 1995 | 2020 |
| Metric | BCRX | TRIN |
|---|---|---|
| Price | $7.20 | $16.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $20.45 | $19.00 |
| AVG Volume (30 Days) | ★ 4.5M | 838.8K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 12.06% |
| EPS Growth | ★ 381.40 | N/A |
| EPS | N/A | ★ 1.35 |
| Revenue | ★ $25,186,000.00 | N/A |
| Revenue This Year | N/A | $34.35 |
| Revenue Next Year | $3.71 | $16.34 |
| P/E Ratio | ★ N/A | $12.53 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.23 | $14.13 |
| 52 Week High | $11.22 | $18.90 |
| Indicator | BCRX | TRIN |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 37.23 |
| Support Level | N/A | $15.64 |
| Resistance Level | $8.83 | $17.35 |
| Average True Range (ATR) | 0.37 | 0.37 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 0.87 | 0.08 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.